It not only reflects the heterogeneous nature of breast tumors per se, but also the heterogeneous nature of the disease, since biopsies from all major breast cancer subtypes were available for use in this study, suggesting that these CAIX inhibitors could be beneficial in all types of breast cancer. This evidence concerns the gene CA9 and breast cancer.